News | July 26, 2025
Solara Active Pharma Sciences consolidated Q1FY26 PAT rises to Rs. 10.52 Cr
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
_256_384.jpg)
Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Revenue increased 11.4 per cent to Rs. 8,545 crore
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Subscribe To Our Newsletter & Stay Updated
